Articles by Louis Garguilo

  1. A Witness To The History of Outsourcing 8/21/2014

    Joe Guiles seems too young and mild-mannered to have been at the outbreak of a revolution that began many years ago. But he witnessed firsthand the inception of what would become the complete penetrability of outsourcing throughout the drug industry. 

  2. Big Pharma Veteran, Peter Bigelow, Will Help “Tell It Like It Is” At Outsourced Pharma West 8/18/2014

    Peter Bigelow is both excited and motivated for Outsourced Pharma West in San Francisco November 10-11, by the targeted subject (drug development and manufacturing outsourcing) and streamlined format (all panelist and attendee discussion; no presentations).

  3. When To Invest In Protein Production: The Risk-Reward Calculation 8/12/2014

    A message to biotech start-ups, scientist-entrepreneurs and life sciences organizations banking on your exciting protein-based drug-discovery programs and technologies: When it comes to the timing of your investment, if you don’t pay now, you might pay (much) more later. 

  4. Learn Pfizer's Guiding Principles For Externalization At Outsourced Pharma West 8/4/2014

    Firelli Alonso-Caplen has been managing outsourcing for 10 years, first at Wyeth and then Pfizer. “The key really is the initial selection process for the CDMO,” she said in a recent conversation regarding our panel at Outsourced Pharma West, in San Francisco, November 10-11. 

  5. ONO Pharmaceutical Strives For Global Sales 7/31/2014

    Gyo Sagara, president, representative director and CEO, challenges his company to enter the cancer field and gain big-pharma relevance.

  6. Discovery Fast Track At GSK Assists Academia And Adds To The Pipeline 7/10/2014

    GlaxoSmithKline (GSK), like so many other pharmaceutical and biotechnology companies, is looking to boost its pipeline. Pearl Huang, Ph.D., vice president and global head of GSK’s Discovery Partnerships with Academia (DPAc), is taking direct aim at the drug discovery concept stage to take up the challenge. By Louis Garguilo, Executive Editor, Outsourced Pharma

  7. Quality, Capacity And Job Security In A CMO Industry Merger -- Part 2 Of Our Interview With CEO Of Newly Formed DPx Holdings B.V.

    This spring Jim Mullen became CEO of DPx Holdings B.V., formed in a $2.65 billion transaction combining JLL Partners’ assets Patheon and Banner Life Sciences, with Royal DSM’s Pharmaceuticals business. In an interview with Outsourced Pharma, Mullen discusses three key components in a merger: quality, capacity and job security.

    With a merger nearing completion and the integration plans underway, Mullen says you have to start with the fundamental ABCs of business. “There are three fundamental questions to get to day one: Do you have the right financial controls? Can you reliably continue to pay your suppliers? Can you receive cash and can you make payroll?

  8. A One-Stop-Shop For Biologics Production In Europe

    A history of bio-pharma outsourcing is writ large upon the chronicles of Cobra Biologics.  

    It is the story of three European manufacturing facilities—a former AstraZeneca plant; one built by a Swedish pharmacy in the early sixties; and a biotech’s IC-funded dream—converging over decades and serving as a barometer of industry trends. The story touches topics of past and present, including the:

    • vicissitudes of big pharma
    • emergence of biotechs and biologics
    • cycles of venture capital and economies
    • growing centricity of outsourcing service providers

    We start with the AstraZeneca facility, in Södertälje, Sweden, 30 kilometers southwest of Stockholm, birthplace of Astra AB. “It was and is today a modern, well equipped facility with two cGMP suites fantastically laid out, and scientists with vast experience producing mammalian and microbial products,” says Peter Coleman, CEO of Cobra Biologics, our bellwether CDMO.